Home Categories Biochemical Engineering MLN9708
A5523912

MLN9708 , ≥98% , 1201902-80-8

CAS NO.:1201902-80-8

Empirical Formula: C20H23BCl2N2O9

Molecular Weight: 517.12

MDL number: MFCD18251437

Pack Size Price Stock Quantity
5MG RMB103.20 In Stock
10MG RMB159.20 In Stock
50MG RMB271.20 In Stock
100MG RMB435.20 In Stock
500MG RMB1575.20 In Stock
1G RMB3119.20 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: >227°C (dec.)
Density  1.47
storage temp.  Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility  DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
pka 1.92±0.20(Predicted)
form  Solid
color  White to Off-White

Description and Uses

Ixazomib citrate is a proteasome inhibitor prodrug for the treatment of multiple myeloma in patients who have received at least one prior therapy in combination with lenalidomide and dexamethasone. The drug was developed by Takeda and reversibly inhibits the protein proteasome subunit β type-5, which is part of the 20S proteasome complex. Ixazomib citrate (XXIV) is hydrolyzed quickly in vivo to give the biologically active compound ixazomib, which presumably is the corresponding boronic acid variant of XXIV.

MLN-9708 is a novel proteasome?inhibitor.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
Safety Statements  24/25
HS Code  29329990

RELATED PRODUCTS